Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
The Ras Gene02:38

The Ras Gene

6.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

36.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-throughput engineering of ligand-activated splicing ribozyme through domain insertion.

bioRxiv : the preprint server for biology·2026
Same author

Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model.

European urology focus·2026
Same author

Endothelial cell-released CD93 contributes to podocyte injury in idiopathic nephrotic syndrome.

Science translational medicine·2026
Same author

Whole-Slide Telepathology Grading of Prostate Cancer in Biopsies Using International Society of Urological Pathology Criteria: Interobserver and Intraobserver Concordance and Implications for Active Surveillance.

The Journal of urology·2025
Same author

Androgen Receptors Promote Oxidative Phosphorylation and Resistance to Palmitate Lipotoxicity in ER-Mutant Breast Cancer.

Endocrinology·2025
Same author

Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatin.

AAPS open·2025

Related Experiment Video

Updated: Oct 7, 2025

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.7K

MIRO2 Regulates Prostate Cancer Cell Growth via GCN1-Dependent Stress Signaling.

Madison Furnish1,2, Dillon P Boulton1,2, Victoria Genther1

  • 1Department of Pharmacology, School of Medicine, University of Colorado Anshutz Medical Campus, Aurora, Colorado.

Molecular Cancer Research : MCR
|January 7, 2022
PubMed
Summary

Mitochondrial Rho GTPase 2 (MIRO2) is upregulated in prostate cancer and drives tumor growth by interacting with General Control Nonderepressible 1 (GCN1). Targeting this MIRO2-GCN1 pathway may offer a new therapeutic strategy for prostate cancer.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Related Experiment Videos

Last Updated: Oct 7, 2025

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.7K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Mitochondrial Biology

Background:

  • Prostate cancer mortality necessitates novel therapeutic targets.
  • Mitochondrial Rho GTPase 2 (MIRO2) mRNA is upregulated in metastatic prostate cancer, correlating with poor survival.

Purpose of the Study:

  • To investigate the role of MIRO2 in prostate cancer progression.
  • To identify novel therapeutic targets within the MIRO2 signaling axis.

Main Methods:

  • Utilized human prostate cancer cell lines (androgen-independent and -sensitive).
  • Performed MIRO2 depletion studies, network analysis of binding partners, and xenograft tumor growth assays in mice.
  • Investigated MIRO2 mutations and interactions with General Control Nonderepressible 1 (GCN1) and GCN2 signaling.

Main Results:

  • MIRO2 depletion impaired prostate cancer cell growth, colony formation, and tumor growth in vivo.
  • MIRO2 interacts with GCN1, which is overexpressed in prostate cancer.
  • MIRO2 is essential for GCN1-mediated GCN2 kinase signaling and activating transcription factor 4 (ATF4) induction, which mediates MIRO2's effect on cell growth.
  • MIRO2, activated GCN2, and ATF4 levels correlate with tumor aggressiveness and are elevated in hypoxic regions.

Conclusions:

  • The MIRO2-GCN1-GCN2-ATF4 axis represents a novel mitochondrial signaling pathway crucial for prostate cancer cell growth.
  • Targeting the MIRO2-GCN1 axis presents a promising therapeutic strategy for halting prostate cancer progression.